ASN Webinar Series Features Groundbreaking Advances in Kidney Care

Join ASN for New Approaches to Transform Outcomes for Kidney Disease and Heart Disease in Patients with Diabetes, a videoconference scheduled for Thursday, December 10, from 4:00 – 5:30 PM EST. 

International clinical experts will review the latest guidelines for both kidney disease and cardiovascular disease, and discuss the most recent clinical trials and promising therapies, including the groundbreaking use of SGLT2 inhibitors to reduce morbidity and mortality.  These are among the first new therapies demonstrated to help prevent the development of heart disease and reduce progression of kidney disease in people with T2DM.

A roundtable of experts from nephrology, cardiology, and endocrinology will consider implications for diabetes, kidney, and heart disease treatment in 2021.  On registering, attendees are invited to submit questions for faculty to consider. 

This is the third in a series developed by the Diabetic Kidney Disease Collaborative (DKD-C) to review and discuss promising therapies for patients with kidney disease and heart disease.  The first two webinars, the recordings for which are available on the ASN DKD-C website, addressed Management of Diabetes and Kidney Disease through COVID-19 and Goal-Directed Medical Therapies for Patients with Diabetic Kidney Disease.  The latter highlighted the DAPA-CKD and EMPEROR-Reduced studies.

The videoconference series will continue in 2021. 

Category:
Subcategory:
Body:

Join ASN for New Approaches to Transform Outcomes for Kidney Disease and Heart Disease in Patients with Diabetes, a videoconference scheduled for Thursday, December 10, from 4:00 – 5:30 PM EST. 

International clinical experts will review the latest guidelines for both kidney disease and cardiovascular disease, and discuss the most recent clinical trials and promising therapies, including the groundbreaking use of SGLT2 inhibitors to reduce morbidity and mortality.  These are among the first new therapies demonstrated to help prevent the development of heart disease and reduce progression of kidney disease in people with T2DM.

A roundtable of experts from nephrology, cardiology, and endocrinology will consider implications for diabetes, kidney, and heart disease treatment in 2021.  On registering, attendees are invited to submit questions for faculty to consider. 

This is the third in a series developed by the Diabetic Kidney Disease Collaborative (DKD-C) to review and discuss promising therapies for patients with kidney disease and heart disease.  The first two webinars, the recordings for which are available on the ASN DKD-C website, addressed Management of Diabetes and Kidney Disease through COVID-19 and Goal-Directed Medical Therapies for Patients with Diabetic Kidney Disease.  The latter highlighted the DAPA-CKD and EMPEROR-Reduced studies.

The videoconference series will continue in 2021.